Core Insights - MiMedx Group, Inc. and Vaporox, Inc. have announced a collaboration for co-promotion and co-marketing of their wound care products, with MiMedx making an investment in Vaporox and obtaining exclusivity rights for potential acquisition discussions [1][2][3] Company Overview - MiMedx is a leader in wound care, focusing on chronic and hard-to-heal wounds, with a vision to be the leading global provider of healing solutions through innovation [5] - Vaporox has developed the Vaporous Hyperoxia Therapy device, which combines ultrasonic mist and concentrated oxygen to treat chronic wounds, receiving FDA clearance for nine types of wounds [2][4] Strategic Goals - The collaboration aims to diversify MiMedx's portfolio and enhance treatment options for clinicians dealing with chronic wounds, leveraging Vaporox's technology alongside MiMedx's placental allografts [3] - Vaporox anticipates that the partnership with MiMedx will accelerate market penetration and create a synergistic offering to reach more patients [3] Clinical Efficacy - Vaporox's VHT has shown wound healing rates exceeding 80% at 20 weeks in clinical studies when used with standard wound care, indicating strong efficacy [3]

Investor Presentation – May 2025 2 • Growing expansion outside of the U.S.; • Our growth expectations in 2025 and beyond, including our growth in surgery, increased funding in targeted research and expandedproduct portfolio; • Expected results of research and development, including that our efforts will innovate and diversify our product portfolio; • Placental-derived products and their potential clinical benefits; • Expectations regarding the reimbursement environment for the Company's products, including ...